Translational Biotechnology: Strategy, Regulation, and Entrepreneurial Pathways

Joshua S. Schoonover, Esq., is an attorney and biotechnology entrepreneur specializing in the translation of early-stage biomedical innovations into clinical and commercial applications. He serves as General Counsel and Co-Lead of Business Development at INmune Bio Inc., a publicly traded biotechnology company developing next-generation immunotherapies. Schoonover's career spans intellectual property law, biologics regulation, and start-up formation. He has led the drafting and prosecution of numerous patent portfolios covering biologic drugs, cell-based therapies, and combination products; structured collaborations between academic laboratories and industry; negotiated in-licensing and out-licensing agreements for biotechnology assets; and guided early-stage ventures through Orphan Drug, Small Business Innovation Research (SBIR), and Regenerative Medicine Advanced Therapy (RMAT) regulatory pathways. He is also an inventor on multiple biologic and combination drug patents. At Harvard Extension School, his teaching focuses on innovation strategy and entrepreneurial leadership in the life sciences, emphasizing the intersection of scientific discovery, intellectual property strategy, and venture creation. Schoonover is a member of the California Bar, registered as House Counsel in Florida, and a registered Patent Attorney with the United States Patent and Trademark Office. He brings more than fifteen years of experience advising and building biotechnology companies.